PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug. GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m. AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition. Merck acquires oncology spinout Modifi Biosciences in deal worth $1.3bn.
PME - Home
A listing of the top 40 creative agencies working on advertising, branding, creative and design projects in the UK healthcare sector. PME – Pharmaceutical Market Europe is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to ...
AstraZeneca’s sipavibart shown to prevent COVID-19 in …
May 16, 2024 · AstraZeneca (AZ) has shared positive results from a late-stage study evaluating the efficacy of its investigational long-acting monoclonal antibody, sipavibart, in preventing COVID-19 in immunocompromised individuals. Despite accounting for approximately 4% of the population, immunocompromised patients make up about 25% of COVID-19 ...
Pfizer’s Paxlovid given FDA permission to be prescribed by US ...
Jul 7, 2022 · The US Food and Drug Administration (FDA) has revised the Emergency Use Authorisation (EUA) for Paxlovid (nirmatrelvir and ritonavir), authorising pharmacists to prescribe the drug to eligible patients. Under the revision, state-licensed pharmacists will be able to prescribe the drug to patients testing positive for COVID-19, on the condition ...
Merck’s adult-specific pneumococcal vaccine Capvaxive ... - PMLiVE
Jun 19, 2024 · Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) for its adult-specific 21-valent pneumococcal conjugate vaccine. Capvaxive is now authorised to prevent invasive pneumococcal disease and pneumococcal pneumonia in individuals aged 18 years and older. Diseases caused by ...
PME - Articles - Pharmaceutical Market Europe
Sep 11, 2024 · PME - Articles. TL STRADOO - Digital biomarkers: reinventing patient monitoring and care. 11 September 2024 Communique - Marketing & Comms. Read More. GLOBAL HEALTH - Causes That Count, Health’ report – key issues affecting global health. 11 September 2024 Communique - Marketing & Comms. Read More.
PME - Magazine Issues
Oct 16, 2024 · PME – Pharmaceutical Market Europe is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts.
AstraZeneca presents positive phase 3 results for Imfinzi ... - PMLiVE
Apr 18, 2023 · AstraZeneca’s (AZ) Imfinzi has shown promising results when used before and after surgery in resectable early-stage non-small cell lung cancer (NSCLC), according to new phase 3 data presented at the American Association for Cancer Research Annual Meeting. Interim results from the AEGEAN study, which is assessing the PD-1/L1 inhibitor in ...
Celgene gets US green light for blockbuster candidate Pomalyst
Feb 11, 2013 · Celgene has been given the go-ahead by the US FDA to market Pomalyst, a new drug for multiple myeloma that has been tipped for $1bn-$1.5bn in annual sales.
Amgen’s Blincyto approved by FDA for new acute lymphoblastic …
Jun 17, 2024 · Amgen’s Blincyto (blinatumomab) has been granted approval by the US Food and Drug Administration (FDA) to treat adult and paediatric patients aged one month and older with an aggressive type of blood cancer. The therapy has been authorised for use in patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute ...